Home › Research › Tau biomarkers
Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?
Koric L, Felician O, Guedj E, Hubert AM, Mancini J, Boucraut J, Ceccaldi M.. Alzheimer disease and associated disorders, 2010-07-01
Topic: Amyloid, tau and blood-test diagnosis
In common forms of Alzheimer disease (AD), anterograde memory impairment is the first deficit to occur. However, the disease, especially in its presenile forms, may also manifest itself through initial deficits that are predominantly of a nonmemory type. These distinct clinical profiles, which reflect the distinct topography of the underlying pathologic processes, may also differ in terms of their cerebrospinal fluid (CSF) markers.
Key findings
- However, the disease, especially in its presenile forms, may also manifest itself through initial deficits that are predominantly of a nonmemory type.
- These distinct clinical profiles, which reflect the distinct topography of the underlying pathologic processes, may also differ in terms of their cerebrospinal fluid (CSF) markers.
- The aim of this study was to assess the levels of total tau, phosphorylated tau, and amyloid-beta 42 peptide in the CSF of "atypical" (nonmemory) early-onset AD patients.
- CSF biomarkers were evaluated in 22 atypical patients, and compared with those from a group of 13 "typical" patients, with a memory onset form of the disease.
Why it matters
This study asked whether the clinical profile of early-onset Alzheimer's disease, memory versus non-memory onset, affects cerebrospinal fluid levels of total tau, phosphorylated tau and amyloid-beta 42. It is a biomarker comparison, so it does not provide a treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders) |
| Journal's citation record | 1 / 4 | Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 25 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.4 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 2 / 6 | Cited 1.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Mathieu Ceccaldi: h-index 33 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20473135) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Koric, L., Felician, O., Guedj, E., Hubert, A. M., Mancini, J., Boucraut, J., et al. (2010). Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease? Alzheimer disease and associated disorders. https://doi.org/10.1097/wad.0b013e3181d712d9
Vancouver
Koric L, Felician O, Guedj E, Hubert AM, Mancini J, Boucraut J, et al. Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease? Alzheimer disease and associated disorders. 2010. doi:10.1097/wad.0b013e3181d712d9. PMID: 20473135.
BibTeX
@article{koric2010-20473135,
author = {Koric, L. and Felician, O. and Guedj, E. and Hubert, A. M. and Mancini, J. and Boucraut, J. and Ceccaldi, M.},
title = {{Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?}},
journal = {Alzheimer disease and associated disorders},
year = {2010},
doi = {10.1097/wad.0b013e3181d712d9},
pmid = {20473135},
url = {https://doi.org/10.1097/wad.0b013e3181d712d9}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Tau biomarkers
Also tagged “biomarkers”
821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.